

Fei Ma

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2122823/publications.pdf>

Version: 2024-02-01

52
papers

1,031
citations

471371

17
h-index

477173

29
g-index

58
all docs

58
docs citations

58
times ranked

1530
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER2-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. <i>Cancer Medicine</i> , 2022, .	1.3	8
2	Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. <i>International Journal of Cancer</i> , 2022, 151, 578-589.	2.3	6
3	Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer. <i>Future Oncology</i> , 2022, , .	1.1	0
4	The inauguration of <i>Cancer Innovation</i> . , 2022, 1, 1-2.		0
5	Pooled analyses of randomized controlled trials on pyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer. , 2022, 1, 119-123.		5
6	Genetic Variations in IFNGR1, BDNF and IL-10 May Predict the Susceptibility to Depression and Anxiety in Chinese Women With Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, 674-680.	1.1	5
7	Profile and outcome of receptor conversion in breast cancer metastases: a nationwide multicenter epidemiological study. <i>International Journal of Cancer</i> , 2021, 148, 692-701.	2.3	11
8	DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis. <i>Annals of Translational Medicine</i> , 2021, 9, 220-220.	0.7	11
9	Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China. <i>Breast</i> , 2021, 55, 30-36.	0.9	8
10	CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. <i>European Journal of Cancer</i> , 2021, 145, 92-108.	1.3	24
11	The association between RAPSN methylation in peripheral blood and breast cancer in the Chinese population. <i>Journal of Human Genetics</i> , 2021, 66, 1069-1078.	1.1	3
12	Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 602222.	1.3	9
13	The molecular tumor burden index as a response evaluation criterion in breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 251.	7.1	19
14	Profile, treatment patterns, and influencing factors of anthracycline use in breast cancer patients in China: A nationwide multicenter study. <i>Cancer Medicine</i> , 2021, 10, 6744-6761.	1.3	5
15	Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	1
16	Breast Cancer in Chinese Females Aged 25 Years and Younger. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	0.6	0
17	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 1359-1368.	2.3	55
18	Mutational characteristics determined using circulating tumor DNA analysis in triple-negative breast cancer patients with distant metastasis. <i>Cancer Communications</i> , 2020, 40, 738-742.	3.7	3

#	ARTICLE	IF	CITATIONS
19	Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 571227.	1.1	5
20	Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage. <i>Frontiers in Oncology</i> , 2020, 10, 902.	1.3	28
21	Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer. <i>Breast</i> , 2020, 53, 111-118.	0.9	8
22	Chromatin modifier MTA1 regulates mitotic transition and tumorigenesis by orchestrating mitotic mRNA processing. <i>Nature Communications</i> , 2020, 11, 4455.	5.8	20
23	Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 59.	2.3	32
24	Clinical spectrum and prognostic value of <i>TP53</i> mutations in circulating tumor DNA from breast cancer patients in China. <i>Cancer Communications</i> , 2020, 40, 260-269.	3.7	18
25	Appropriate arrangement of cancer treatment after COVID-19 epidemic peaks in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2717-2718.	1.2	1
26	Clinical features and prognostic factors for extracranial oligometastatic breast cancer in China. <i>International Journal of Cancer</i> , 2020, 147, 3199-3205.	2.3	8
27	Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. <i>International Journal of Cancer</i> , 2020, 147, 3490-3499.	2.3	11
28	Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	7
29	Depression, anxiety, and their associated factors among Chinese early breast cancer in women under 35 years of age: A cross sectional study. <i>Current Problems in Cancer</i> , 2020, 44, 100558.	1.0	17
30	Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer. <i>Breast</i> , 2020, 49, 261-266.	0.9	26
31	Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. <i>Breast</i> , 2020, 52, 17-22.	0.9	12
32	Polymorphisms of <i>MTHFR</i> and <i>TYMS</i> predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. <i>Cancer Communications</i> , 2019, 39, 1-12.	3.7	7
33	Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>BioDrugs</i> , 2019, 33, 357-371.	2.2	23
34	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 5212-5220.	3.2	60
35	Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis. <i>BioDrugs</i> , 2019, 33, 373-389.	2.2	18
36	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. <i>BMC Cancer</i> , 2019, 19, 442.	1.1	26

#	ARTICLE	IF	CITATIONS
37	The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. <i>Cancer Communications</i> , 2019, 39, 1-10.	3.7	86
38	The Effect of Polymorphism in UGT1A4 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Patients With Breast Cancer in China. <i>Clinical Breast Cancer</i> , 2019, 19, e370-e375.	1.1	3
39	Central venous catheter-related complications in the treatment of cancer patients: A prospective study of over 124,000 catheter days.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18264-e18264.	0.8	0
40	The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study. <i>Cancer Communications</i> , 2018, 38, 1-11.	3.7	16
41	The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 1-11.	1.1	89
42	Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. <i>Scientific Reports</i> , 2017, 7, 5995.	1.6	25
43	Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis. <i>Molecular and Clinical Oncology</i> , 2017, 7, 167-172.	0.4	8
44	Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer. <i>Journal of Breast Cancer</i> , 2017, 20, 321.	0.8	21
45	Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3105-3112.	0.8	168
46	Landscape of somatic mutations in different subtypes: Advanced breast cancer with circulating tumour DNA analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23039-e23039.	0.8	0
47	ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. <i>Oncotarget</i> , 2016, 7, 66020-66031.	0.8	75
48	Adoptive immunotherapy combined chemoradiotherapy for non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 433-438.	0.7	4
49	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma. <i>Medicine (United States)</i> , 2016, 95, e3134.	0.4	13
50	Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells. <i>Oncotarget</i> , 2016, 7, 65993-66002.	0.8	19
51	Molecular Landscape of Tp53 Mutations in Breast Cancer and Their Utility for Predicting Response to HER-Targeted Therapy in HER2 Amplification-Positive and HER2 Mutation-Positive Amplification-Negative Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
52	Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis in Cancer Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0